Fractyl Health Inc. (GUTS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial
Fractyl Health NASDAQ: GUTS is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion.
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health Q2 Earnings Call Highlights
Fractyl Health NASDAQ: GUTS said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year.
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Discusses 1-Year REMAIN-1 Data Demonstrating Durable Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Fractyl Health Q1 Earnings Call Highlights
Fractyl Health NASDAQ: GUTS said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement developments during the company's first-quarter 2026 earnings call.
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Loses 77.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fractyl Health, Inc. (GUTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts
Fractyl Health offers a buy-the-dip opportunity after an overreaction to underwhelming 6-month pilot data for its Revita device. Revita's pivotal Phase 3 obesity trial is well-funded, with topline results expected in 2H 2026 and a low statistical bar for success. Weight regain in the Revita arm was driven by a single site; excluding it, results align with prior positive data, supporting optimism for pivotal readout.
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Fractyl Health, Inc. ( GUTS ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Brian Luque - Head of Investor Relations & Corporate Development Harith Rajagopalan - Co-Founder, CEO & Director Lisa Davidson - CFO & Treasurer Conference Call Participants Chi Meng Fong - BofA Securities, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Michael Ulz - Morgan Stanley, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to Fractyl Health Third Quarter 2025 Financial Results and Business Update Call.
